Selank
Also known as: Thr-Lys-Pro-Arg-Pro-Gly-Pro, Tuftsin analogue, Selanque, TP-7 (glyproline heptapeptide), Selank heptapeptide
Synthetic heptapeptide anxiolytic / nootropic / immunomodulator (glyproline family, tuftsin analogue)
What it is
Selank is a synthetic peptide used in Russia as a prescription anxiolytic, and in the nootropics community worldwide for anxiety relief and cognitive support. It works by modulating the brain's opioid and neurotransmitter systems to reduce stress and improve focus. Approved in Russia for anxiety disorders; not FDA-approved; regulatory status varies by country.
The scientific side
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the endogenous immunopeptide tuftsin. Multiple mechanisms have been proposed in the reviewed literature: (1) Inhibition of enkephalin-degrading enzymes (enkephalinases) in human plasma, thereby prolonging the half-life of endogenous leu-enkephalin — this is suggested as a primary anxiolytic mechanism (PMIDs: 11550013, 32342318, 29181670, 15344652, 11443939). (2) Positive allosteric modulation of GABA-A receptors, with a modulatory site apparently distinct from but potentially overlapping with benzodiazepine and antipsychotic binding sites. (3) Upregulation of spontaneous inhibitory postsynaptic currents in hippocampal CA1 neurons. (4) Modulation of Th1/Th2 cytokine balance and immune function, including induction of IFN-α gene expression and suppression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, TGF-β1) under stress conditions (PMIDs: 19882898, 18577961, 32621722). (5) Enhancement of brain-derived neurotrophic factor (BDNF) regulation in the hippocampus and prefrontal cortex. (6) Anticoagulant activity demonstrated by thromboelastography. One review also mentions enhancement of BDNF and HGF/c-Met pathways critical to neuroplasticity. GABA receptor-related mechanism is noted in a pharmacology review.
Class: Synthetic heptapeptide anxiolytic / nootropic / immunomodulator (glyproline family, tuftsin analogue)
Modified Forms
The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.
N-Acetyl Selank Amidate
N-Acetyl Selank Amidate is structurally identical to Selank with N-terminal acetylation and C-terminal amidation added to resist peptidase cleavage. These modifications extend enzymatic stability relative to the parent sequence. No peer-reviewed studies specific to this modified form were identified in any literature search — all mechanism and safety assumptions are extrapolated from Selank data. Community users typically administer it intranasally at doses reported to be lower than standard Selank, though this dose adjustment is empirical and has no experimental basis in published research. Regulatory status mirrors Selank: unapproved in all reviewed jurisdictions.
How dosing differs: Community use typically mirrors Selank intranasal protocols (250–400 mcg) or slightly lower due to assumed stability advantage. No published dose-finding data exists for this modified form.
Key differences from parent: Same terminal modifications as N-Acetyl Semax Amidate applied to the Selank sequence: N-terminal acetylation and C-terminal amidation for enzymatic stability. No independent pharmacological studies distinguish this form from standard Selank.
Administration & storage
- Administration
- Intraperitoneal injection (animal studies; PMIDs: 3632230431625062326217223265182631236882312436792885310012432865)Intranasal administration (human clinical study; PMID: 18454096)Oral administration (human clinical study; PMID: 18454096)Intraperitoneal injection — preventive scheme in mice (antiviral studies; PMID: 19882898)
- Storage
- One abstract notes Selank is sold online as lyophilized powder for injection or in nasal spray formulations. No specific storage temperature, duration, or conditions are stated in any reviewed abstract.
- Cautions
- Selank is described as a 'poorly studied' drug with GABAergic mechanisms; significant evaluation of abuse potential, dependence, and withdrawal has not been adequately conducted prior to public access.,Selank has not completed clinical trials according to one reviewed abstract; it is characterized as a 'research peptide'.,Anticoagulant effects have been demonstrated in animal thromboelastography studies; potential bleeding risk in humans is unknown.,Selank modulates GABA-A receptor activity and cytokine balance; interactions with other GABAergic drugs (e.g., benzodiazepines, antipsychotics) have been observed in vitro and in vivo — combined use may produce unpredictable effects (PMIDs: 30255741, 28293190, 28280289).,Sterile technique is essential when handling any injectable preparation to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification. One reviewed abstract characterizes Selank as a 'poorly studied Russian drug' sold to US consumers 'inexplicably as a dietary supplement,' and notes it…
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Anxiety and anxiety-phobic disorders (generalized anxiety disorder, phobic disorders, somatoform disorders, neurasthenia) Human observational
- In 62 patients with GAD and neurasthenia, Selank showed comparable anxiolytic effects to medazepam, plus antiasthenic and psychostimulant effects; administered intranasally and orally. PMID 18454096 Zozulia et al., Zhurnal nevrologii i psikhiatrii, 2008
- Comparative study (60 patients, phobic-anxiety and somatoform disorders): pronounced anxiolytic and mild nootropic effects of Selank demonstrated; anxiolytic effect lasted a week after last dose; positive impact on quality of life. PMID 25176261 Medvedev et al., Zhurnal nevrologii i psikhiatrii, 2014
- Randomized controlled trial: combination of Selank + phenazepam produced earlier positive effect and decreased undesirable side effects of phenazepam (memory/attention impairment, sedation, etc.) vs. phenazepam monotherapy in anxiety-phobic, hypochondriac and somatoform disorders. PMID 26356395 Medvedev et al., Zhurnal nevrologii i psikhiatrii, 2015
- Immunomodulation / cytokine regulation Mixed
- In vitro: Selank at 10^-7 M completely suppressed IL-6 gene expression in peripheral blood of depressed patients. In vivo: Changes in Th1/Th2 cytokine balance observed in patients with GAD and neurasthenia receiving Selank for 14 days. PMID 18577961 Uchakina et al., Zhurnal nevrologii i psikhiatrii, 2008
- Animal study: Selank (100 mcg/kg/day i.p.) under 20-day social stress reduced IL-1β, IL-6, TNF-α, and TGF-β1 concentrations toward control values in rats. PMID 32621722 Yasenyavskaya et al., Current Reviews in Clinical and Experimental Pharmacology, 2021
- Selank induced IFN-α gene expression in vivo in mice without affecting IL-4, IL-10, or TNF-α; mechanism may relate to Th1/Th2/Treg cytokine equilibrium modulation. PMID 19882898 Ershov et al., Voprosy virusologii, 2009
- Antiviral activity (influenza and other viruses) Animal studies only
- Pronounced antiviral effect against influenza A/Aichi 2/68 (H3N2) in vitro and in vivo in mice; preventive administration scheme (24 h before inoculation) showed highest efficacy, completely suppressing viral reproduction in cell culture; highest animal survival with preventive scheme. PMID 19882898 Ershov et al., Voprosy virusologii, 2009
- Structural fragments of Selank demonstrated antiviral properties (specific results not available in abstract text). PMID 20506839 Andreeva et al., Doklady biological sciences, 2010
- Memory and cognitive protection (including ethanol-induced impairment) Animal studies only
- Selank (0.3 mg/kg/day, 7 days, i.p.) produced cognitive-stimulating effect in aged rats and prevented ethanol-induced memory/attention disturbances during alcohol withdrawal; prevented ethanol-induced BDNF increase in hippocampus and frontal cortex. PMID 31625062 Kolik et al., Bulletin of experimental biology and medicine, 2019
- Attenuation of morphine withdrawal signs Animal studies only
- Single i.p. injection of Selank (0.3 mg/kg) reduced total index of naloxone-precipitated morphine withdrawal syndrome by 39.6%, attenuated convulsive reactions, ptosis, posture disorders; slightly inferior to diazepam (2 mg/kg, 49.3% reduction). PMID 36322304 Konstantinopolsky et al., Bulletin of experimental biology and medicine, 2022
- Stress-protective / hepatoprotective effects under stress Animal studies only
- Selank i.p. (100, 300, 1000 μg/kg) before each session of chronic foot-shock stress in rats reduced hepatocyte degenerative changes; maximum effect at 300 μg/kg. PMID 31243679 Fomenko et al., Bulletin of experimental biology and medicine, 2019
- Selank i.p. (100, 300, 1000 μg/kg) before restraint stress decreased lipid peroxidation markers and increased antioxidant activity in rat liver; at 1000 μg/kg reduced aminotransferases in serum. PMID 28853100 Fomenko et al., Bulletin of experimental biology and medicine, 2017
- Gastrointestinal microbiota preservation and colon morphology under stress Animal studies only
- Selank i.p. (80, 250, 750 μg/kg) before chronic restraint stress restored intestinal microbiota (obligate microflora) in rats, presumably via neurotropic and immunotropic mechanisms. PMID 31236882 Mukhina et al., Bulletin of experimental biology and medicine, 2019
- Selank i.p. (80, 250, 750 μg/kg) before restraint stress reduced pathomorphological manifestations in colon wall (atrophy, inflammation, mast cell changes) and decreased corticosterone levels in rats. PMID 32651826 Mukhina et al., Bulletin of experimental biology and medicine, 2020
- Anxiety reduction in Parkinson's disease model Animal studies only
- Selank decreased anxiety levels in rats with 6-OHDA-induced Parkinson's-like parkinsonism in the elevated cross-shaped maze; did not affect motor activity or passive defensive behavior. PMID 28702721 Slominsky et al., Doklady biological sciences, 2017
- Modulation of resting-state brain functional connectivity Human observational
- In 52 healthy participants, resting-state fMRI before and 5 and 20 min after Selank injection revealed specific effects on functional connectivity between the right amygdala and right temporal cortex (fusiform, inferior and middle temporal, and parahippocampal gyri). PMID 32342318 Panikratova et al., Doklady biological sciences, 2020
- Anticoagulant effects Animal studies only
- Thromboelastography in rats showed Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) demonstrated maximal anticoagulation potency among tested glyproline oligopeptides, shifting parameters to hypocoagulation direction. PMID 29181670 Rogozinskaya & Lyapina, Bulletin of experimental biology and medicine, 2017
- Enhancement of diazepam anxiolytic effect under chronic mild stress Animal studies only
- In unpredictable chronic mild stress conditions in rats, combined Selank + diazepam was most effective in reducing stress-induced anxiety; individual Selank was most effective in reducing anxiety caused by test substance administration course. PMID 28280289 Kasian et al., Behavioural Neurology, 2017
Safety signals
- Characterized as 'poorly studied' with GABAergic mechanism; inadequate evaluation of abuse potential, dependence, and withdrawal before public access; sold as a dietary supplement in the US without regulatory approval. PMID 34396551
- Found in seized pharmaceutical preparations not completing clinical trials; identified as a potentially dangerous molecule by Belgian regulatory/analytical laboratory. PMID 31667971
- Anticoagulant effects demonstrated by thromboelastography in rats — Selank showed the maximal anticoagulation potency among tested glyproline peptides. PMID 29181670
- Selank decreased the ratio of GABA+ neurons differentiated from mouse embryonic stem cells by approximately 61% vs. control in vitro — potential implications for neurodevelopmental safety not yet established. PMID 29063333
- Selank modulates GABA-A receptors as a positive allosteric modulator and can block the modulatory activity of diazepam and olanzapine — potential for unpredictable pharmacodynamic drug interactions. PMID 30255741
Contraindications
- No explicit contraindications are stated in any reviewed abstract. The literature notes Selank is poorly studied and has not completed clinical trials, making formal contraindication data unavailable. PMID 34396551
Protocol
250 mcg intranasal, twice daily. Cycle: 2-4 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intraperitoneal | 0.3 mg/kg (single intraperitoneal injection) | Single dose | animal | Research PMID 36322304 |
| Intraperitoneal | 0.3 mg/kg/day for 7 days | 7 days | animal | Research PMID 31625062 |
| Intraperitoneal | 100 mcg/kg/day | 20 days | animal | Research PMID 32621722 |
| Intraperitoneal | 80, 250, and 750 μg/kg | Administered 15 min before each stress session (chronic restraint stress model) | animal | Research PMID 46 |
| Intraperitoneal | 80, 250, and 750 μg/kg | Administered 15 min before each stress session (chronic restraint stress model) | animal | Research PMID 32651826 |
| Intraperitoneal | 80, 250, and 750 μg/kg | Chronic restraint stress period | animal | Research PMID 31236882 |
| Intraperitoneal | 100, 300, and 1000 μg/kg | Administered 15 min before each chronic foot-shock stress session | animal | Research PMID 31243679 |
| Intraperitoneal | 100, 300, and 1000 μg/kg | Acute and chronic restraint stress conditions | animal | Research PMID 28853100 |
| Not specified in abstract | 100 μg/kg | Not specified (single or repeated doses in behavioral test) | animal | Research PMID 12432865 |
| In vitro | IC50 15 μM (for enkephalinase inhibition in plasma) | In vitro assay | in_vitro | Research PMID 11550013 |
| In vitro | IC50 20 μM (for enkephalin-degrading enzyme inhibition in human serum) | In vitro assay | in_vitro | Research PMID 11443939 |
| In vitro | 10^-7 M (in vitro IL-6 suppression) | In vitro assay | in_vitro | Research PMID 18577961 |
| In vitro (applied to brain slices) | 1–8 μM (applied to hippocampal slices; no significant dose-dependence in this range) | Ex vivo slice preparation | in_vitro | Research PMID 28361410 |
| intranasal | 250 mcg | twice daily · 2-4 weeks | biohackers and nootropic users seeking anxiolytic effects without sedation | [Community] |
| intranasal | 500 mcg | twice daily · 2-4 weeks | biohackers and nootropic users with prior Selank experience, seeking stronger anxiolytic and nootropic effect | [Community] |
| intranasal | 250 mcg | once daily (morning) · 2-4 weeks | beginners or users sensitive to anxiolytics, first-time Selank users | [Community] |
| intranasal | 750 mcg | twice daily · 2-4 weeks | experienced biohackers seeking enhanced nootropic or anxiolytic effect | [Community] |
| subcutaneous injection | 300 mcg | once daily · 2-4 weeks | biohackers preferring injectable administration for more consistent bioavailability | [Community] |
| subcutaneous injection | 500 mcg | once daily · 2-4 weeks | experienced biohackers using injectable Selank for nootropic and anxiolytic purposes | [Community] |
| intranasal | 250 mcg | as needed (acute dosing) · single dose or short-term acute use | nootropic users and biohackers managing situational anxiety or acute stress events | [Community] |
| intranasal | 500 mcg | once daily (morning) · 30 days | biohackers stacking Selank with Semax for synergistic nootropic and anxiolytic effects | [Community] |
| intranasal | 500 mcg | twice daily · 10-14 days on, 10-14 days off (cycling) | biohackers concerned about tolerance or tachyphylaxis with chronic use | [Community] |
Blends containing this peptide
All studies (27)
- PMID 18454096 Human observational
Anxiety and anxiety-phobic disorders (generalized anxiety disorder, phobic disorders, somatoform dis - PMID 25176261 Human observational
Anxiety and anxiety-phobic disorders (generalized anxiety disorder, phobic disorders, somatoform dis - PMID 26356395 Human observational
Anxiety and anxiety-phobic disorders (generalized anxiety disorder, phobic disorders, somatoform dis - PMID 32342318 Human observational
Modulation of resting-state brain functional connectivity - PMID 18577961 Mixed
Immunomodulation / cytokine regulation - PMID 19882898 Mixed
Immunomodulation / cytokine regulation - PMID 32621722 Mixed
Immunomodulation / cytokine regulation - PMID 46
80, 250, and 750 μg/kg Intraperitoneal (animal) - PMID 11443939
IC50 20 μM (for enkephalin-degrading enzyme inhibition in human serum) In vitro (in_vitro) - PMID 11550013
IC50 15 μM (for enkephalinase inhibition in plasma) In vitro (in_vitro) - PMID 12432865
100 μg/kg Not specified in abstract (animal) - PMID 20506839 Animal studies only
Antiviral activity (influenza and other viruses) - PMID 28280289 Animal studies only
Enhancement of diazepam anxiolytic effect under chronic mild stress - PMID 28361410
1–8 μM (applied to hippocampal slices; no significant dose-dependence in this range) In vitro (applied to brain slices) (in_vitro) - PMID 28702721 Animal studies only
Anxiety reduction in Parkinson's disease model - PMID 28853100 Animal studies only
Stress-protective / hepatoprotective effects under stress - PMID 29063333
Selank decreased the ratio of GABA+ neurons differentiated from mouse embryonic stem cells by approximately 61% vs. control in vitro — potential implications fo - PMID 29181670 Animal studies only
Anticoagulant effects - PMID 30255741
Selank modulates GABA-A receptors as a positive allosteric modulator and can block the modulatory activity of diazepam and olanzapine — potential for unpredicta - PMID 31236882 Animal studies only
Gastrointestinal microbiota preservation and colon morphology under stress - PMID 31243679 Animal studies only
Stress-protective / hepatoprotective effects under stress - PMID 31625062 Animal studies only
Memory and cognitive protection (including ethanol-induced impairment) - PMID 31667971
Found in seized pharmaceutical preparations not completing clinical trials; identified as a potentially dangerous molecule by Belgian regulatory/analytical labo - PMID 32651826 Animal studies only
Gastrointestinal microbiota preservation and colon morphology under stress - PMID 34396551
Characterized as 'poorly studied' with GABAergic mechanism; inadequate evaluation of abuse potential, dependence, and withdrawal before public access; sold as a - PMID 36322304 Animal studies only
Attenuation of morphine withdrawal signs - PMID 41490200
Frequently asked
What is Selank and what is it used for?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as an analogue of the endogenous immunopeptide tuftsin. Published studies have investigated it primarily as an anxiolytic and immunomodulator. Human clinical studies report anxiolytic effects comparable to benzodiazepines in patients with generalized anxiety disorder and neurasthenia, and one randomized controlled trial found it reduced side effects when added to phenazepam therapy. Animal studies report antiviral, stress-protective, and memory-preserving effects (PMIDs: 19882898, 31625062). It has not completed clinical trials for any indication and is characterized as a 'research peptide' in the reviewed literature.
What dose of Selank should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: Animal studies have used doses ranging from 80 μg/kg to 1000 μg/kg intraperitoneally (PMIDs: 32651826, 31243679). Human clinical studies used intranasal and oral routes but did not specify numerical doses in the reviewed abstracts. No human pharmacokinetic dose-finding data are available in the reviewed literature.
Is Selank legal / FDA approved?
The reviewed literature does not state a formal FDA approval or regulatory classification for Selank. One abstract describes it as a 'poorly studied Russian drug' sold 'inexplicably as a dietary supplement' to US consumers, and another describes it as a 'research peptide' found in seized preparations that has not completed clinical trials. For current regulatory status, please consult the FDA website or a licensed healthcare provider directly.
How does Selank work (mechanism of action)?
Multiple mechanisms have been proposed in the reviewed literature: (1) Inhibition of enkephalin-degrading enzymes in plasma, prolonging endogenous leu-enkephalin half-life (PMIDs: 11550013, 32342318); (2) Positive allosteric modulation of GABA-A receptors at a site distinct from but potentially overlapping with benzodiazepine binding sites; (3) Upregulation of spontaneous inhibitory postsynaptic currents in hippocampal CA1 neurons; (4) Modulation of Th1/Th2 cytokine balance and IFN-α induction (PMIDs: 19882898, 18577961); (5) Regulation of BDNF in hippocampus and prefrontal cortex; (6) Anticoagulant effects. One review also cites BDNF and HGF/c-Met pathway enhancement.
Can I stack Selank with diazepam or other benzodiazepines?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: One animal study found combined Selank + diazepam was the most effective at reducing stress-induced anxiety in chronic mild stress conditions, but individual Selank was most effective for anxiety caused by the drug administration course itself. In vitro, Selank was shown to block the modulatory activity of diazepam on GABA receptors, suggesting a complex interaction. A clinical study added Selank to phenazepam and found reduced side effects. The safety profile of combined use in humans is not established.
Does Selank have antiviral properties?
Animal and in vitro studies suggest antiviral activity. One study found Selank completely suppressed influenza A (H3N2) viral reproduction in cell culture when administered 24 hours before inoculation, and the preventive scheme also showed the highest animal survival in vivo in mice. Structural fragments of Selank also demonstrated antiviral properties in another study. No human antiviral trials are reported in the reviewed literature.
Is Selank safe? What are the known side effects?
Selank is described as poorly studied in the reviewed literature, and no comprehensive human safety data are available. Key signals from the literature include: (1) It is characterized as a 'poorly studied' compound with inadequate evaluation of abuse potential, dependence and withdrawal; (2) It has not completed clinical trials and has been identified by regulatory analysts as a potentially dangerous molecule; (3) Anticoagulant effects have been found in animal studies; (4) It modulates GABA-A receptors and may interact with benzodiazepines and antipsychotics in unpredictable ways (PMIDs: 30255741, 28293190). Human clinical studies (PMIDs: 25176261, 26356395) noted favorable tolerability compared to phenazepam, but these were not designed as comprehensive safety trials. Please consult a licensed healthcare provider.
What is the difference between Selank and Semax?
Both are synthetic Russian regulatory peptides studied as nootropics. One reviewed study compared their effects on resting-state brain functional connectivity in 52 healthy humans: Selank is described as an anxiolytic and Semax as a nootropic; they showed both general and specific effects on functional connectivity between the right amygdala and right temporal cortex. Both inhibit enkephalin-degrading enzymes in human serum (IC50 ~10 μM for Semax, ~15-20 μM for Selank; PMIDs: 11443939, 11550013). Selank is an analogue of tuftsin; Semax is an analogue of ACTH 4-10. The comparative clinical and safety data between the two compounds are limited in the reviewed literature.
Can Selank help with opiate or morphine withdrawal?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. For reference, one animal study found that a single intraperitoneal injection of Selank at 0.3 mg/kg reduced the total index of naloxone-precipitated morphine withdrawal syndrome by 39.6% in morphine-dependent rats, attenuating convulsive reactions, ptosis, and posture disorders — though it was slightly less effective than diazepam (2 mg/kg, 49.3% reduction) in the same model. No human data on this use are available in the reviewed literature.
Where can I buy Selank?
I don't recommend vendors or sources. Please consult a licensed provider.